Prodia Shares Seen Attractive for Speculative Buy on Solid Fundamentals

JAKARTA, Investortrust.id — PT Prodia Widyahusada Tbk or PRDA remains attractive for a speculative buy as analysts point to solid fundamentals and positive sector sentiment supporting potential near term price gains.

The healthcare services provider’s shares closed at Rp 2,370 on Friday, Jan 23, 2026, down 1.25 percent on the day, but still up 3.04 percent year to date.

Technical analyst Herditya Wicaksana of MNC Sekuritas said PRDA was trading in an attractive range for speculative strategies.

He noted that the stock had support at Rp 2,340 and resistance at Rp 2,400, with a near term target price range of Rp 2,440 to Rp 2,480.

From a fundamentals perspective, Prodia continued to post resilient performance despite macroeconomic pressure.

As of the third quarter of 2025, the company recorded consolidated revenue of Rp 1.58 trillion, supported by diversified service segments.

President Director Dewi Muliaty said inflation and rupiah volatility had weighed on consumer purchasing power while pushing up operating costs.

Despite these challenges, Prodia maintained profitability and balance sheet strength.

The company booked earnings before interest and tax of Rp 111 billion, profit before tax of Rp 143 billion, tax expense of Rp 28.7 billion, and net profit of Rp 114 billion through September 2025.

As of the same period, Prodia reported total assets of Rp 2.58 trillion, liabilities of Rp 268 billion, and equity of Rp 2.31 trillion.

Growth was supported by contributions from multiple business lines.

The esoteric testing segment generated revenue of about Rp 380 billion, while non laboratory services contributed Rp 117 billion, highlighting effective business diversification.

Management said operational resilience was underpinned by efficiency initiatives and ongoing expansion, supported by positive operating cash flow to fund working capital and capital expenditure.

External sentiment also turned supportive for the healthcare sector.

The government allocated Rp 114 trillion in the 2026 draft state budget for healthcare, while broader equity market momentum provided an additional tailwind for healthcare stocks.

Looking ahead, Prodia said it would continue to strengthen performance through clinic and digital service expansion, including its U by Prodia platform, tighter cost efficiency, and broader regional partnerships.

The company is also expanding its referral network to Timor Leste, Malaysia, and Taiwan as part of its ambition to develop a Southeast Asia referral laboratory, while increasing its corporate client base with integrated healthcare solutions.